Friday, May 31, 2024, Chicago, Illinois, 11:45 AM – 12:45 PM Central Time (12:45 PM – 1:45 PM Eastern Time)

Lunch with the Investigators: Hepatobiliary Cancers

A CME Hybrid Symposium Held in Conjunction with the 2024 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400

Program Schedule — Central Time
11:15 AM – 11:45 AM — Registration and Lunch
11:45 AM – 12:45 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Robin K (Katie) Kelley, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF)
San Francisco, California

Additional faculty to be announced.
Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Incyte Corporation, Jazz Pharmaceuticals Inc, and Taiho Oncology Inc.
Program Schedule — Central Time
11:15 AM – 11:45 AM — Registration and Lunch
11:45 AM – 12:45 PM — Educational Meeting

Discussion Topics

  • MODULE 1: Recent Developments in the Management of Early- and Intermediate-Stage Hepatocellular Carcinoma (HCC)
  • MODULE 2: First-Line Therapy for Advanced HCC and Biliary Tract Cancers (BTCs)
  • MODULE 3: Integration of Targeted Therapy into the Management of Advanced BTCs

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hepatobiliary cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Recall recently presented and emerging clinical trial results with anti-PD-L1 antibody therapy in combination with anti-VEGF therapy for HCC in patients with a high risk of recurrence after curative resection or ablation or those receiving transarterial chemoembolization for unresectable disease, and consider the potential role of these strategies in clinical practice.
  • Appreciate available and recently updated Phase III data with the use of novel first-line treatment strategies for unresectable or metastatic HCC, and discuss how these regimens can be optimally integrated into patient care.
  • Evaluate the rationale for and available data with the use of anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies in patients with HCC to determine the current role of these novel regimens.
  • Discuss the biological justification for the evaluation of immune checkpoint inhibitors for advanced biliary tract cancers and develop strategies to optimally incorporate anti-PD-1/ PD-L1 antibody-based approaches into the care of patients with these diseases.
  • Assess key data sets supporting the FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement to optimally select and sequence these agents.
  • Develop an understanding of available clinical trial findings supporting the use of IDH inhibitors for patients with advanced cholangiocarcinoma and an IDH1 mutation in order to determine the applicability of this therapeutic strategy in current clinical practice.
  • Evaluate available and emerging clinical trial findings with HER2-directed therapies in patients with HER2-positive biliary tract cancers, and contemplate the current and potential future use of these agents or regimens for appropriately selected individuals.
  • Recall available and emerging data with investigational agents and strategies currently in clinical testing for HCC and biliary tract cancers, and where applicable refer eligible patients for trial participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Kelley — Advisory Committees (Payments to Institution): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck; Consulting Agreements (Payments to Self): Compass Therapeutics, Exact Sciences Corporation, GSK, J-Pharma Co Ltd, Kinnate Biopharma, Moderna, Regeneron Pharmaceuticals Inc, Tyra Biosciences; Contracted Research (Payment to Institution for Trial Conduct): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Compass Therapeutics, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Partner Therapeutics, QED Therapeutics, Servier Pharmaceuticals LLC, Surface Oncology, Taiho Oncology Inc, Tyra Biosciences; Independent Data Monitoring Committees (Unpaid Service): Genentech, a member of the Roche Group, Merck. Additional faculty to be announced.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Incyte Corporation, Jazz Pharmaceuticals Inc, and Taiho Oncology Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hepatobiliary cancers.

There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2024 ASCO Annual Meeting.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.